DSIP (Delta Sleep-Inducing Peptide)

Like a promising lab notebook from the 1970s that someone photocopied and now sells as a finished product. The early sketch looked interesting, but the work to prove it safe and effective was never completed. What you can buy today is hype around an unfinished idea, not a tested medicine.

DSIP is a small endogenous neuropeptide originally proposed to be a humoral sleep factor that promotes slow-wave (delta) EEG activity. Its actual mechanism is poorly defined and disputed. No specific receptor has been definitively identified, and reported effects in animals and in vitro span sleep architecture modulation, stress/HPA-axis attenuation (lowering cortisol and ACTH responses), thermoregulation, antinociception and antioxidant activity. This broad, non-specific range of claimed actions itself argues against a single clear pharmacological pathway. In research settings it has been given by injection, since the peptide would be rapidly degraded if taken orally.

Research contexts. Not proven uses, and not recommendations.

Human testing peaked in the late 1970s and 1980s with small studies, the best-known being a double-blind intravenous trial in people with chronic insomnia (Schneider-Helmert and Schoenenberger, Experientia 1981) reporting improved sleep without daytime sedation. Other small open or weakly controlled trials examined insomnia, pain and withdrawal states with mixed results. Sample sizes were tiny, designs were mostly open-label or underpowered, and the work was never replicated in modern large RCTs. There is no Phase 2/3 development programme. DSIP's status as a true natural sleep factor remains scientifically contested. The evidence is suggestive but does not meet modern standards for efficacy or safety.

• !No marketing authorisation anywhere. DSIP is not an approved medicine, so there is no regulator-vetted evidence of efficacy, safety or manufacturing quality.
• !Evidence is decades old, small-scale and unreplicated. Modern RCTs do not exist.
• !Its identity as a genuine endogenous sleep factor and its mechanism remain scientifically disputed.
• !Grey-market 'research chemical' supply has no guarantee of purity, identity, dose accuracy, sterility or endotoxin control.
• !Injecting unregulated material carries infection, contamination and dosing-error risks.
• !Long-term human safety is essentially unstudied.
• !Marketing hype vastly outruns the evidence. The name oversells what has ever been demonstrated.

DSIP is not a licensed medicine in the UK and holds no MHRA marketing authorisation. It is an experimental peptide sold online as an unlicensed 'research chemical' marked 'for research use only / not for human consumption', a label used to sidestep medicines regulation. Selling or supplying it for human use as a medicine without authorisation contravenes the Human Medicines Regulations 2012, and the material is unregulated for quality and safety. It is not a controlled drug under the Misuse of Drugs Act. There is no legitimate route to obtain DSIP for human use in the UK outside an approved clinical trial.

1. 01
   The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide — Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M, Pflugers Archiv (Pflugers Arch) (1978)

   Original isolation, sequencing and synthesis of the DSIP nonapeptide; foundational characterisation paper in the DSIP series.

2. 02
   The influence of synthetic DSIP (delta-sleep-inducing peptide) on disturbed human sleep — Schneider-Helmert D, Schoenenberger GA, Experientia (1981)

   Small double-blind study in chronic insomniacs; the most-cited human sleep trial. Reported improved sleep without daytime sedation.

3. 03
   A clinical trial with DSIP — Kaeser HE, European Neurology (Eur Neurol) (1984)

   Small clinical evaluation of DSIP in insomnia; illustrative of the limited, weakly controlled human data of the era.

4. 04
   Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP) — Schoenenberger GA, European Neurology (Eur Neurol) (1984)

   Review documenting DSIP's broad, non-specific 'multivariate' actions and the unsettled question of its true physiological role.

5. 05
   PubMed search: delta sleep-inducing peptide (DSIP) literature, PubMed (search across the DSIP literature) (2026)

   Breadth search across the DSIP literature; useful for confirming the absence of modern large RCTs.